New One-Minute COVID-19 Test Detects Antibodies from Single Drop of Blood
By HospiMedica International staff writers Posted on 30 May 2020 |
Image: An INSTI test for SARS-CoV-2 (Photo courtesy of bioLytical Laboratories Inc.)
A one-minute test for antibodies to SARS-CoV-2 is currently being developed based on an innovative testing technology that detects antibodies within one minute from a single drop of blood.
The test is being developed on bioLytical Laboratories Inc.’s (Richmond, BC, Canada) proprietary INSTI platform. bioLytical will receive advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop the one-minute test for antibodies to SARS-CoV-2.
INSTI is made in Canada and known for its fast, easy-to-use, and accurate serological tests. As an antibody test, an INSTI test for SARS-CoV-2 can be an important part of the testing strategy in Canada and around the world. By detecting antibodies to COVID-19 in a single drop of blood, INSTI does not require additional materials such as swabs. Along with the test device, all materials required to perform the test are provided together in one small pouch; leading this testing platform to become known as “a lab in a pouch.”
The INSTI SARS-CoV-2 test development project is funded by NRC IRAP and aims to accelerate research and development for solutions to address COVID-19 related gaps and challenges identified by health experts.
Related Links:
bioLytical Laboratories Inc.
The test is being developed on bioLytical Laboratories Inc.’s (Richmond, BC, Canada) proprietary INSTI platform. bioLytical will receive advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop the one-minute test for antibodies to SARS-CoV-2.
INSTI is made in Canada and known for its fast, easy-to-use, and accurate serological tests. As an antibody test, an INSTI test for SARS-CoV-2 can be an important part of the testing strategy in Canada and around the world. By detecting antibodies to COVID-19 in a single drop of blood, INSTI does not require additional materials such as swabs. Along with the test device, all materials required to perform the test are provided together in one small pouch; leading this testing platform to become known as “a lab in a pouch.”
The INSTI SARS-CoV-2 test development project is funded by NRC IRAP and aims to accelerate research and development for solutions to address COVID-19 related gaps and challenges identified by health experts.
Related Links:
bioLytical Laboratories Inc.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans